194 related articles for article (PubMed ID: 38228919)
21. Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases.
Vakrakou AG; Tzanetakos D; Evangelopoulos ME; Argyrakos T; Tzartos JS; Anagnostouli M; Andreadou E; Koutsis G; Velonakis G; Toulas P; Gialafos E; Dimitrakopoulos A; Psimenou E; Stefanis L; Kilidireas C
Ther Adv Neurol Disord; 2021; 14():17562864211006503. PubMed ID: 34046086
[TBL] [Abstract][Full Text] [Related]
22. Tumefactive demyelinating lesions as a first clinical event: Clinical, imaging, and follow-up observations.
Jeong IH; Kim SH; Hyun JW; Joung A; Cho HJ; Kim HJ
J Neurol Sci; 2015 Nov; 358(1-2):118-24. PubMed ID: 26333950
[TBL] [Abstract][Full Text] [Related]
23. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
[TBL] [Abstract][Full Text] [Related]
24. Tumefactive demyelinating lesions (TDLs): A case series of clinicoradiological features.
Jain RS; Khan I; Kandelwal K; Desai T
Clin Neurol Neurosurg; 2017 Nov; 162():91-94. PubMed ID: 28987645
[TBL] [Abstract][Full Text] [Related]
25. Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders.
Sechi E; Krecke KN; Messina SA; Buciuc M; Pittock SJ; Chen JJ; Weinshenker BG; Lopez-Chiriboga AS; Lucchinetti CF; Zalewski NL; Tillema JM; Kunchok A; Monaco S; Morris PP; Fryer JP; Nguyen A; Greenwood T; Syc-Mazurek SB; Keegan BM; Flanagan EP
Neurology; 2021 Sep; 97(11):e1097-e1109. PubMed ID: 34261784
[TBL] [Abstract][Full Text] [Related]
26. A challenging diagnosis of late-onset tumefactive multiple sclerosis associated to cervicodorsal syringomyelia: doubtful CT, MRI, and bioptic findings: Case report and literature review.
Conforti R; Capasso R; Galasso R; Cirillo M; Taglialatela G; Galasso L
Medicine (Baltimore); 2016 Sep; 95(36):e4585. PubMed ID: 27603348
[TBL] [Abstract][Full Text] [Related]
27. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study.
Altintas A; Petek B; Isik N; Terzi M; Bolukbasi F; Tavsanli M; Saip S; Boz C; Aydin T; Arici-Duz O; Ozer F; Siva A
Mult Scler; 2012 Oct; 18(10):1448-53. PubMed ID: 22419670
[TBL] [Abstract][Full Text] [Related]
28. Neuroimaging and clinicopathological differences between tumefactive demyelinating lesions and sentinel lesions of primary central nervous system lymphoma.
Sun C; Han J; Lin Y; Qi X; Li C; Liu J; Qiu F
Front Immunol; 2022; 13():986473. PubMed ID: 36059526
[TBL] [Abstract][Full Text] [Related]
29. Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions.
Cha S; Pierce S; Knopp EA; Johnson G; Yang C; Ton A; Litt AW; Zagzag D
AJNR Am J Neuroradiol; 2001; 22(6):1109-16. PubMed ID: 11415906
[TBL] [Abstract][Full Text] [Related]
30. Clinical and radiological characteristics of 17 Chinese patients with pathology confirmed tumefactive demyelinating diseases: follow-up study.
Yao J; Huang D; Gui Q; Chen X; Lou X; Wu L; Cheng C; Li J; Wu W
J Neurol Sci; 2015 Jan; 348(1-2):153-9. PubMed ID: 25499757
[TBL] [Abstract][Full Text] [Related]
31. Tumefactive Demyelinating Lesions in Children: A Rare Case of Conus Medullaris Involvement and Systematic Review of the Literature.
Pérez CA; Patnaik A; Oommen S; Redko A; Mathis SB
J Child Neurol; 2020 Sep; 35(10):690-699. PubMed ID: 32552343
[TBL] [Abstract][Full Text] [Related]
32. [Comparison of tumefactive demyelinating lesions and glioma by clinical presentations and neuroimaging studies].
Liu J; Qiao W; Zheng K; Zhao H; Qian H; Yao S; Duan F; Qiu F; Qi X
Zhonghua Yi Xue Za Zhi; 2014 Oct; 94(39):3047-51. PubMed ID: 25549675
[TBL] [Abstract][Full Text] [Related]
33. Proton magnetic resonance spectroscopy differentiates tumefactive demyelinating lesions from gliomas.
Ikeguchi R; Shimizu Y; Abe K; Shimizu S; Maruyama T; Nitta M; Abe K; Kawamata T; Kitagawa K
Mult Scler Relat Disord; 2018 Nov; 26():77-84. PubMed ID: 30237108
[TBL] [Abstract][Full Text] [Related]
34. Immunopathology of Tumefactive Demyelinating Lesions-From Idiopathic to Drug-Related Cases.
Vakrakou AG; Brinia ME; Svolaki I; Argyrakos T; Stefanis L; Kilidireas C
Front Neurol; 2022; 13():868525. PubMed ID: 35418930
[TBL] [Abstract][Full Text] [Related]
35. Phenotyping variants of tumefactive demyelinating lesions according to clinical and radiological features-A case series.
Boyle T; Fernando SL; Drummond J; Fontes A; Parratt J
Front Neurol; 2023; 14():1092373. PubMed ID: 36816572
[TBL] [Abstract][Full Text] [Related]
36. Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy.
Malhotra HS; Jain KK; Agarwal A; Singh MK; Yadav SK; Husain M; Krishnani N; Gupta RK
Mult Scler; 2009 Feb; 15(2):193-203. PubMed ID: 19181773
[TBL] [Abstract][Full Text] [Related]
37. Clinical and radiological characteristics and outcomes of patients with recurrent or relapsing tumefactive demyelination.
Pervin I; Ramanathan S; Cappelen-Smith C; Vucic S; Reddel SW; Hardy TA
Mult Scler Relat Disord; 2024 Feb; 82():105408. PubMed ID: 38219394
[TBL] [Abstract][Full Text] [Related]
38. Tumour-like lesions in multiple sclerosis.
Jamroz-Wiśniewska A; Janczarek M; Belniak E; Stelmasiak Z; Bartosik-Psujek H
Neurol Neurochir Pol; 2008; 42(2):161-7. PubMed ID: 18512174
[TBL] [Abstract][Full Text] [Related]
39. A Rare and Challenging Presentation of Acute Hemorrhagic Leukoencephalitis With Tumefactive Demyelinating Lesions in a 41-Year-Old Male.
Iltaf Mairajuddin S; Salim Inshasi JS; Channa RMA; Anwar Siddiqi S; Shaffi Al Madani AAR; Flayyih R
Cureus; 2024 Apr; 16(4):e58282. PubMed ID: 38752096
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors in Tumefactive demyelinating lesions: A retrospective study.
Plowman RS; Varma H
J Neurol Sci; 2021 Sep; 428():117591. PubMed ID: 34333380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
